Table 1.
Patient’s characteristics.
Fig 1.
Box plot depicting SelectMDx® scores for negative vs. positive biopsy findings.
Fig 2.
Box plot depicting SelectMDx® scores for different Gleason scores.
Each paired boxplot with a statistically significance in means, was indicated using asterisks with the following, standardized significance codes: * p < 0.05, ** p < 0.01, *** p < 0.001. Of note, when dichotomizing into cohorts with patients ≤GS 7a and >7a, a higher GS was associated with a significantly higher SelectMDx® score (58.82 ± 25.08% vs. 34.48 ± 28.55%; p = 0.01).
Fig 3.
Box plot depicting SelectMDx® scores for different PI-RADS scores.
Each paired boxplot with a statistically significance in means, was indicated using asterisks with the following, standardized significance codes: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. The differences in means of SelectMDx® results according to PI-RADS Scores 2–5 were significant in ANOVA (p = 0.002).
Fig 4.
ROC curve for PI-RADS, SelectMDx® urine test marker, PSA and the novel scoring system (combination of PI-RADS, history of prior biopsy and SelectMDx®).
Table 2.
Novel sum score derived from the combination of PI-RADS, history of prior biopsy and SelectMDx® score.